
| 10.1155/2020/9465398
http://scihub22266oqcxt.onion/10.1155/2020/9465398
 33134398!7568776!33134398
free
free
free
|  
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\33134398.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
J+Immunol+Res 2020 ; 2020 (�): 9465398 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
|
Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping #MMPMID33134398Lu Y; Wang Y; Zhang Z; Huang J; Yao M; Huang G; Ge Y; Zhang P; Huang H; Wang Y; Li H; Wang WJ Immunol Res 2020[]; 2020 (�): 9465398 PMID33134398show ga
This new decade has started with a global pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), precipitating a worldwide health crisis and economic downturn. Scientists and clinicians have been racing against time to find therapies for COVID-19. Repurposing approved drugs, developing vaccines and employing passive immunization are three major therapeutic approaches to fighting COVID-19. Chicken immunoglobulin Y (IgY) has the potential to be used as neutralizing antibody against respiratory infections, and its advantages include high avidity, low risk of adverse immune responses, and easy local delivery by intranasal administration. In this study, we raised antibody against the spike (S) protein of SARS-CoV-2 in chickens and extracted IgY (called IgY-S) from egg yolk. IgY-S exhibited high immunoreactivity against SARS-CoV-2 S, and by epitope mapping, we found five linear epitopes of IgY-S in SARS-CoV-2 S, two of which are cross-reactive with SARS-CoV S. Notably, epitope SIIAYTMSL, one of the identified epitopes, partially overlaps the S1/S2 cleavage region in SARS-CoV-2 S and is located on the surface of S trimer in 3D structure, close to the S1/S2 cleavage site. Thus, antibody binding at this location could physically block the access of proteolytic enzymes to S1/S2 cleavage site and thereby impede S1/S2 proteolytic cleavage, which is crucial to subsequent virus-cell membrane fusion and viral cell entry. Therefore, the feasibility of using IgY-S or epitope SIIAYTMS-specific IgY as neutralizing antibody for preventing or treating SARS-CoV-2 infection is worth exploring.|*Epitope Mapping[MESH]|Administration, Intranasal[MESH]|Animals[MESH]|Antibodies, Neutralizing/administration & dosage/immunology/isolation & purification[MESH]|Antibodies, Viral/administration & dosage/immunology/isolation & purification[MESH]|Betacoronavirus/*immunology[MESH]|COVID-19[MESH]|COVID-19 Serotherapy[MESH]|Chickens[MESH]|Coronavirus Infections/epidemiology/immunology/*therapy/virology[MESH]|Cross Reactions[MESH]|Feasibility Studies[MESH]|Humans[MESH]|Immunization, Passive/methods[MESH]|Immunoglobulins/administration & dosage/immunology/*isolation & purification[MESH]|Pandemics[MESH]|Pneumonia, Viral/epidemiology/immunology/*therapy/virology[MESH]|SARS-CoV-2[MESH]
  
DeepDyve Pubget Overpricing | 
|